Tempted by Biotech in Toronto

Courtesy of Bill Latta After 14 years in North Carolina's Research Triangle Park, Judd Berman decided it was time for a change. As he looked around, says Berman, former director of high-throughput chemistry for GlaxoSmithKline, he was certain he'd end up in San Diego, where he has relatives. But an unexpected invitation from a Toronto biotech startup called Affinium Pharmaceuticals intrigued him. "I fell in love with the people as well as the city itself," Berman explains, a year after reloca

| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

After 14 years in North Carolina's Research Triangle Park, Judd Berman decided it was time for a change. As he looked around, says Berman, former director of high-throughput chemistry for GlaxoSmithKline, he was certain he'd end up in San Diego, where he has relatives. But an unexpected invitation from a Toronto biotech startup called Affinium Pharmaceuticals intrigued him.

"I fell in love with the people as well as the city itself," Berman explains, a year after relocating to Toronto. "Everyone at Affinium had deep personal commitments to research. And Toronto is pretty dynamic. It's a 'tossed salad' city having many distinct cultural entities. There's so much going on, it's just a terrific place to work and live."

Berman is senior vice president for chemistry at Affinium, a drug discovery company spun off from research done at the University of Toronto (UofT) (cf. map-1) and the Ontario Cancer Institute (cf. map-2). ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Ted Agres

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide